Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Cantargia AB logo — A Swedish listed biotechnology company

Cantargia AB

A Swedish listed biotechnology company

Founded 2010 Sweden Sweden 32 employees Post-IPO Equity Total: $257.00M Biotechnology, Health and Wellness +1

General Information

Company Name Cantargia AB
Founded Year 2010
Location Sweden Sweden
Founders / Decision Makers
Team member
Employees 32
Industries Biotechnology, Health and Wellness, Medical Devices
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Cantargia AB. To contact Cantargia AB, visit cantargia.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Cantargia AB compare?

A PDF of Cantargia AB and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Cantargia AB soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Cantargia AB

Cantargia is a Swedish listed biotechnology company that focuses on developing antibody-based therapies targeting IL1RAP. The company's clinical programs include nadunolimab, which is currently in phase II development for the treatment of cancer, and CAN10 in phase I development for autoimmune/inflammatory diseases. Founded in 2010, Cantargia is headquartered in Sweden. The company recently secured a significant kr250.00M Post-IPO Equity investment on 21 June 2022. This investment is indicative of the confidence that investors have in Cantargia's potential to make a meaningful impact in the field of biotechnology with its innovative antibody therapies.

Taxonomy: antibody-based therapies, clinical programs, IL1RAP, cancer treatment, autoimmune diseases, inflammatory diseases, leukemic stem cells, hematopoietic stem cells, Chronic myeloid leukemia, Acute myeloid leukemia, Acute lymphocytic leukemia, antibody-based therapy, Swedish listed company, phase II development

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity kr250.00M -
21 Jun 2022
Venture Round kr7.00M 2
Sunstone Capital
Sunstone Capital, Lubio Science
05 Jul 2013

Cantargia AB Alternatives & Competitors

View All Alternatives
Cantargia AB vs
Immunic Therapeutics
Immunic Therapeutics United States

Immunic is a biotechnology company developing small molecule therapies for chronic inflammatory and...

Post-IPO Equity
91 employees
Biotechnology, Health and Wellness
Cantargia AB vs
Altheia Science
Altheia Science Italy

Altheia Science develops treatments for autoimmune diseases and cancer using innovative tools. Found...

Series A
6 employees
Biotechnology, Health Care
Cantargia AB vs
Alder Biopharmaceuticals
Alder Biopharmaceuticals

Dedicated to alleviating human suffering with safer and better antibody therapeutics through innovat...

Post-IPO Equity
Biotechnology, Health Care
View all alternatives

FAQ About Cantargia AB

A Swedish listed biotechnology company
Cantargia AB was founded in 2010.
Cantargia AB is headquartered in Sweden.
Cantargia AB operates in Biotechnology, Health and Wellness and Medical Devices. Its work centres on antibody-based therapies, clinical programs, IL1RAP and cancer treatment.
Cantargia AB has approximately 32 employees.
Cantargia AB has completed 2 funding rounds, raising a total of $257.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Cantargia AB include Immunic Therapeutics, Altheia Science, Alder Biopharmaceuticals, Visterra Inc., VBL Therapeutics (Nasdaq:VBLT). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cantargia AB and Immunic Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Cantargia AB, https://bouncewatch.com/company/cantargia, updated 9 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes